Lion HTDS,update from website.
httddirect.com
httddirect.com
httddirect.com
There can be no doubt, strategy for "Fast Track" approval by FDA will be of paramount importance. To this end, HTTD will address this consideration that could make the product TUBERCIN readily available after successful treatment of patients abroad in the last Fourteen Years.
Mission Statement
HTTD INCORPORATED intends to carry out the mission of administering the use of Tubercin on an international basis. Tubercin is an immunostimulant agent against cancer. Hard to treat diseases will also be considered.
Patents
Presently, HTTD has the patent rights for Korea, Japan and the United States. The Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese patent was issued on June 12, 1998 (Registration No. 2790447). The United States patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and Spain).
Management of the Company realizes the potential value of the patent and license rights of TUBERCIN. Legal specialists in patent and license registration have been retained to protect HTTD's interest by pursuit of patent protection.
Management intends to hire an in-house attorney to vigorously and continuously monitor and evaluate Tubercin's progress in receiving the final patent rights internationally, particularly in Europe.
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer. There have been no indications of any adverse side effects in human trials. There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived.
A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient. To this end the Company has been assisted by outside consultants reviewing the research data and human trials involving TUBERCIN to see specifically whereby incidents of dual treatment produced favorable results in terms of moving toward indication of prolongation of the life of the cancer patient.
There is recognition that morphine is an trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. |
